| Titre |
Étude Pilote de Phase II Sur l'Effet du méthylphénidate Sur la Fonction Cognitive Des Patientes en rémission d'un Cancer du Sein |
| Protocole ID |
CogMet |
| ClinicalTrials.gov ID |
NCT02970500 |
| Type(s) de cancer |
Sein |
| Phase |
Phase II |
| Type étude |
Support |
| Médicament |
Méthylphénidate |
| Institution |
CHU DE QUEBEC – UNIVERSITE LAVAL
|
| Ville |
Québec |
| Investigateur(trice) principal(e) |
Dr Bruno Gagnon
|
| Coordonnateur(trice) |
Mauranne Labonté
418-525-4444 poste 52715
|
| Statut |
 Actif en recrutement |
| Critètes d'éligibilité |
-
Breast cancer stade I, II or III
-
had received chemotherapy and/or radiotherapy
-
being in remission of her breast cancer
-
complaining of cognitive impairment
|
| Critètes d'exclusion |
-
Current or recent use of psychostimulant drugs
-
Women receiving drugs like:
-
Anticoagulants
-
Antidepressants
-
Drugs (cocaine)
-
Erythropoietin
-
Drugs acting on the cerebral dopaminergic system, including drugs that inhibit monoamine oxidase
-
Currently taking John's wort, natural medicines for depression or supplements for fatigue.
-
Conditions that may increase the risk of cognitive impairment or toxicity of methylphenidate such as :
-
Pregnancy and breastfeeding
-
Migraine, headache
-
Bipolar status
-
Cerebral tumor or any brain injury
-
Metastatic cancer
-
Alcohol addiction
-
Drug
-
Active Major depression
-
Parkinson disease
-
Dementia
-
Epilepsia,
-
Glaucoma
-
Cardiovascular diseases
-
Auto-immunes and chronic inflammatory disease
-
Narcolepsia
-
Pheochromocytome
-
Thyrotoxicosis
-
Motor tic, Gilles de la Tourette syndrome
-
Anxiety
|
Groupe d'étude en oncologie du Québec